[go: up one dir, main page]

RU2447077C2 - Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования - Google Patents

Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования Download PDF

Info

Publication number
RU2447077C2
RU2447077C2 RU2007109866/04A RU2007109866A RU2447077C2 RU 2447077 C2 RU2447077 C2 RU 2447077C2 RU 2007109866/04 A RU2007109866/04 A RU 2007109866/04A RU 2007109866 A RU2007109866 A RU 2007109866A RU 2447077 C2 RU2447077 C2 RU 2447077C2
Authority
RU
Russia
Prior art keywords
methyl
propyl
isothiazolo
dihydro
oxo
Prior art date
Application number
RU2007109866/04A
Other languages
English (en)
Other versions
RU2007109866A (ru
Inventor
Брайан АКИЛА (US)
Брайан Акила
Майкл Хауард БЛОК (US)
Майкл Хауард БЛОК
Одри ДЕЙВИС (US)
Одри ДЕЙВИС
Яячандран ЭЗХУТХАЧАН (US)
Яячандран ЭЗХУТХАЧАН
Тимоти ПОНТЗ (US)
Тимоти ПОНТЗ
Даниел Джон РАССЕЛ (US)
Даниел Джон Рассел
Мария-Елена ТЕОКЛИТОУ (US)
Мария-Елена Теоклитоу
Сяолань ЧЖЭН (US)
Сяолань Чжэн
Сандра Энн ФИЛЛА (US)
Сандра Энн Филла
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37904998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2447077(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2007109866A publication Critical patent/RU2007109866A/ru
Application granted granted Critical
Publication of RU2447077C2 publication Critical patent/RU2447077C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к (R)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метил-пропил]-4-метил-бензамиду, по существу свободному от (S)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамида, или его фармацевтически приемлемой соли, которые обладают свойствами ингибитора Eg5. Изобретение относится также к фармацевтической композиции, содержащей указанное соединение или его фармацевтически приемлемую соль. 2 н. и 2 з.п. ф-лы, 27 пр.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131

Claims (4)

1. (R)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамид или его фармацевтически приемлемая соль, который, по существу, свободен от (S)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамида.
2. (R)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамид или его фармацевтически приемлемая соль по п.1, в котором (S)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамид присутствует в количестве не более чем 2 мас.%.
3. (R)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамид или его фармацевтически приемлемая соль по п.1, в котором (S)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамид присутствует в количестве не более чем 1 мас.%.
4. Фармацевтическая композиция, обладающая свойством ингибитора Eg5, которая содержит (R)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамид или его фармацевтически приемлемую соль, который, по существу, свободен от (S)-N-(3-амино-пропил)-N-[1-(5-бензил-3-метил-4-оксо-4,5-дигидро-изотиазоло[5,4-d]пиримидин-6-ил)-2-метилпропил]-4-метил-бензамида, и по меньшей мере один фармацевтически приемлемый носитель, разбавитель или наполнитель.
RU2007109866/04A 2004-08-18 2005-08-16 Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования RU2447077C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60236604P 2004-08-18 2004-08-18
US60/602,366 2004-08-18

Publications (2)

Publication Number Publication Date
RU2007109866A RU2007109866A (ru) 2008-09-27
RU2447077C2 true RU2447077C2 (ru) 2012-04-10

Family

ID=37904998

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007109866/04A RU2447077C2 (ru) 2004-08-18 2005-08-16 Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования

Country Status (18)

Country Link
US (3) US20080293744A1 (ru)
EP (1) EP1781674A1 (ru)
JP (1) JP2008509977A (ru)
KR (1) KR20070046176A (ru)
CN (1) CN101027309B (ru)
AU (1) AU2005273705B8 (ru)
BR (1) BRPI0514390A (ru)
CA (1) CA2575188A1 (ru)
IL (1) IL180810A0 (ru)
MX (1) MX2007001953A (ru)
MY (1) MY141233A (ru)
NO (1) NO20071005L (ru)
RU (1) RU2447077C2 (ru)
SA (1) SA05260258B1 (ru)
TW (1) TW200616977A (ru)
UA (1) UA89201C2 (ru)
UY (1) UY29070A1 (ru)
ZA (1) ZA200701082B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20125635B (en) * 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
MY162507A (en) 2009-06-29 2017-06-15 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
HUE043703T2 (hu) 2011-09-02 2019-09-30 Incyte Holdings Corp Heterociklusos aminok PI3K inhibitorokként
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112016007467B1 (pt) 2013-10-04 2022-09-20 Infinity Pharmaceuticals, Inc Compostos heterocíclicos e usos dos mesmos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
MX388606B (es) 2015-02-27 2025-03-19 Incyte Holdings Corp Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion.
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2024103067A1 (en) * 2022-11-10 2024-05-16 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2000109296A (ru) * 1997-09-12 2002-01-10 Новартис Аг Новые пиримидин-4-оны и пиримидин-4-тионы в качестве фунгицидов

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
TR199801813T2 (xx) 1996-03-11 1998-12-21 Novartis Ag B�cek �ld�r�c� olarak pirimidin-4- on t�revleri.
KR100628407B1 (ko) 1998-12-23 2006-09-26 브리스톨-마이어스 스퀴브 파마 컴파니 Ｘａ 인자 억제제로서의 질소 함유 헤테로비시클릭 화합물
US6545005B1 (en) 1999-09-16 2003-04-08 Curtis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CZ20021428A3 (cs) 1999-10-27 2002-11-13 Cytokinetics, Inc. Způsoby a kompozice vyuľívající chinazoliny
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
EP1343505A1 (en) 2000-12-11 2003-09-17 Tularik Inc. Cxcr3 antagonists
US6809102B2 (en) * 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
MXPA03008691A (es) 2001-03-29 2003-12-12 Bristol Myers Squibb Co Metodo para tratamiento de enfermedades proliperativas usando inhibidores eg5.
AU2002305205A1 (en) 2001-04-20 2002-11-05 Jingrong Cao 9-deazaguanine derivatives as inhibitors of gsk-3
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1458726B1 (en) * 2001-12-06 2009-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002364128B2 (en) 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1481077B1 (en) * 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60231439D1 (de) 2001-12-06 2009-04-16 Merck & Co Inc Mitotische kinesinhemmer
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
DK1511734T3 (da) * 2002-04-17 2010-08-02 Cytokinetics Inc Forbindelser, præparater og fremgangsmåder
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
JP2006506401A (ja) 2002-05-23 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US7557115B2 (en) 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006502230A (ja) 2002-10-11 2006-01-19 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
MXPA05003830A (es) 2002-10-11 2005-06-23 Cytokinetics Inc Compuestos, composiciones y metodos.
JP2006515886A (ja) 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
WO2004091547A2 (en) 2003-04-10 2004-10-28 Cytokinetics, Inc Compounds, compositions, and methods
JP2007500213A (ja) 2003-05-07 2007-01-11 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US20070066591A1 (en) 2003-05-14 2007-03-22 Xiangping Qian Compounds, compositions, and methods
US20070032536A1 (en) 2003-05-15 2007-02-08 Xianping Qian Compounds, compositions and methods
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
MXPA05013142A (es) 2003-06-20 2006-03-17 Chiron Corp Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
US20050165089A1 (en) * 2003-10-06 2005-07-28 Gustave Bergnes Compounds, compositions and methods
EP1680420A4 (en) * 2003-11-07 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
SG148202A1 (en) 2003-11-25 2008-12-31 Novartis Vaccines & Diagnostic Quinazolinone compounds as anticancer agents
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
DE602005012069D1 (de) 2004-04-06 2009-02-12 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
PL1753723T3 (pl) 2004-05-21 2009-01-30 Novartis Vaccines & Diagnostics Inc Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych
TW200612958A (en) 2004-06-18 2006-05-01 Chiron Corp Substituted imidazole derivatives
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
AR050921A1 (es) 2004-08-18 2006-12-06 Astrazeneca Ab Heterociclos fusionados seleccionados y usos de los mismos
KR20070072598A (ko) * 2004-10-19 2007-07-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 인돌 및 벤지미다졸 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2000109296A (ru) * 1997-09-12 2002-01-10 Новартис Аг Новые пиримидин-4-оны и пиримидин-4-тионы в качестве фунгицидов

Also Published As

Publication number Publication date
AU2005273705B2 (en) 2009-12-10
ZA200701082B (en) 2008-07-30
UA89201C2 (ru) 2010-01-11
CN101027309B (zh) 2010-10-27
KR20070046176A (ko) 2007-05-02
SA05260258B1 (ar) 2009-12-22
NO20071005L (no) 2007-05-16
UY29070A1 (es) 2006-03-31
AU2005273705B8 (en) 2010-01-28
CA2575188A1 (en) 2006-02-23
TW200616977A (en) 2006-06-01
MY141233A (en) 2010-03-31
US20080293744A1 (en) 2008-11-27
IL180810A0 (en) 2007-06-03
CN101027309A (zh) 2007-08-29
US20060041129A1 (en) 2006-02-23
RU2007109866A (ru) 2008-09-27
EP1781674A1 (en) 2007-05-09
BRPI0514390A (pt) 2008-06-10
MX2007001953A (es) 2007-05-09
JP2008509977A (ja) 2008-04-03
AU2005273705A1 (en) 2006-02-23
US20090099210A1 (en) 2009-04-16
US7498333B2 (en) 2009-03-03

Similar Documents

Publication Publication Date Title
RU2447077C2 (ru) Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования
RU2463302C2 (ru) Производные 4-(3-аминопиразол)пиримидина для применения в качестве ингибиторов тирозинкиназы для лечения злокачественного новообразования
RU2416611C2 (ru) Бициклические амиды как ингибиторы киназы
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
MY143466A (en) Inhibitors of tyrosine kinases
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
WO2003059898A3 (en) Eponemycin and epoxomicin analogs and uses thereof
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
ATE383360T1 (de) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
WO2007024651A3 (en) Bridged n-bicyclic sulfonamido inhibitors of gamma secretase
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
WO2004014868A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MEP20908A (en) Thienopyrazoles
BRPI0407841A (pt) inibidores heterocìclicos de quinase
WO2003053971A8 (en) Pyridoquinoxaline antivirals
PT1463504E (pt) Composicoes compreendendo epotilonas e sua utilizacao para o tratamento de sindroma carcinoide
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
WO2004037166A3 (en) Therapeutic guanidines

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120817